It has been previously suggested that dopamine receptor D2 antagonists, such as, prochlorperazine dimaleate, exert anti-fibrotic effects in models of diabetic hepatic fibrosis and non-alcoholic steatohepatitis induced liver fibrogenesis by regulating TGF-β1/Smad in hepatic stellate cells, and decreasing YAP levels in macrophages, respectively [59, 60]. Here, DRD2 is linked to metabolic dysfunction-associated steatohepatitis.